Cancer Biomarkers Market Updates by 2031
2022 年癌症生物标志物市场价值为 184.3636 亿美元,很可能进入美国到 2031 年,预计将达到 348.5712 亿美元,预计 2022-2031 年复合年增长率为 11.1%
生物标志物,一种生物分子,存在于血液、组织或其他体液中,是标准或异常过程的标志。生物标志物用于观察身体对疾病或病症治疗的反应程度。
市场洞察
新产品发布和 FDA 批准以及技术进步推动市场增长
市场参与者正在制造各种癌症生物标志物,以提供最大的优势和早期诊断。 2021 年 4 月,安进推出了 Biomarker Assist,该计划旨在帮助更多转移性(IV 期)非小细胞肺癌 (NSCLC) 患者获得生物标志物测试。诊断时的生物标志物测试是让患者接受正确治疗的关键的第一步。通过 Biomarker Assist,符合条件的患者可以节省生物标记物测试费用。
此外, 2022 年 3 月,Vela Diagnostics 推出了新的基于重点(60 个基因)和全面(525 个基因)的下一代测序 (NGS) 组合,用于检测福尔马林固定石蜡包埋 (FFPE) 组织样本中的 RNA 和 DNA 癌症生物标志物。新型泛癌基因Panel包括重点型OncoKey SL 60 Plus Panel和综合型OncoKey SL 525 Plus Panel。
此外,2021年12月,BioGenex推出了三种新的一抗免疫组织化学(IHC)抗体,包括CD8A、CD163和CD56,用于癌症诊断。
此外,癌症免疫疗法的最新进展已经在患者的长期临床反应中显现出来。癌症免疫疗法正在迅速取代传统的治疗标准,并扩大癌症患者的治疗前景。研究人员致力于寻找血液中可以发出癌症出现信号的分子。为了诊断卵巢癌和前列腺癌,癌症抗原 (CA)125 和前列腺特异性抗原 (PSA) 与其他测试一起使用。
此外,高通量组学技术(包括基因组学、蛋白质组学、转录组学和代谢组学)的进步加快了生物标志物发现的步伐。最近,通过液体活检识别循环肿瘤DNA的概念已转向临床现实。癌症免疫治疗协会 (SITC) 重新召集了生物标志物免疫工作组,以审查最先进的技术,确定当前的障碍,并为该领域提出建议。因此,最近的技术进步使许多潜在的生物标志物成为可能,并重新开发新的生物标志物,并推动癌症生物标志物市场。
< strong>战略洞察
市场洞察- 机遇
发展中国家的新兴市场在预测期内为市场提供利润丰厚的机会
新兴亚太地区等市场正在为重要的市场参与者扩大业务创造充足的机会。由于发展中国家有大量的癌症患者以及医疗旅游业的增长,大多数主要参与者都集中在印度、中国等新兴国家。大多数新兴国家都是医疗旅游的首选地。
根据澳大利亚健康与福利研究所预计,2021 年将诊断出 151,000 例新癌症病例。此外,根据马来西亚医疗旅游理事会的数据,2021 年,将有超过 200 万人前往马来西亚进行医疗保健,使医疗旅游收入翻倍至约 6.8 亿。该地区手术成本低,技术先进,等待时间短,可能会增加对癌症生物标志物的需求。
因此,新兴国家不断增长的医疗旅游业和亚太地区癌症患病率的上升预计将为预测期内癌症生物标志物市场的参与者提供巨大的增长机会。< /span>
基于生物标记类型的见解
癌症生物标志物市场根据生物标志物类型分为遗传生物标志物、蛋白质生物标志物等。蛋白质生物标志物细分市场在 2022 年占据最大市场份额,预计在预测期内将实现最高增长率。
癌症生物标志物市场,按生物标志物类型划分 - 2022 年和 2031 年
分析基于技术的见解
癌症生物标志物市场根据分析技术分为组学技术、成像技术、免疫分析、细胞遗传学、和生物信息学。组学技术领域在 2022 年占据最大的市场份额,预计在 2022 年和 2031 年期间将实现最高增长率。
基于癌症类型的见解
癌症生物标志物市场根据癌症类型分为乳腺癌、肺癌、前列腺癌、白血病、膀胱癌等。 2022年,其他细分市场占据最大市场份额。然而,肺癌细分市场预计在未来几年将出现最快的增长速度。
基于应用程序的见解
根据应用,癌症生物标志物市场分为诊断、研发、预后等。 2022 年,预测领域占据最大的市场份额。此外,预计同一细分市场在预测期内的复合年增长率最高。
癌症生物标志物市场的公司高度采用并购等无机和有机策略。下面列出了最近的一些主要市场发展:
- 2022 年 3 月,Vela Diagnostics 推出全新聚焦(60 个基因)和全面(525 个基因)二代测序(NGS)基于福尔马林固定石蜡包埋 (FFPE) 组织样本的 RNA 和 DNA 癌症生物标志物检测面板。新的泛癌基因Panel包括重点型OncoKey SL 60 Plus Panel和综合型OncoKey SL 525 Plus Panel。
- 2022 年 3 月,隶属于美国国立卫生研究院的国家癌症研究所启动了分子表征计划用于小儿肿瘤。该计划为新诊断出中枢神经系统肿瘤并在儿童肿瘤学组附属医院接受治疗的儿童、青少年和年轻人提供肿瘤分子表征(也称为生物标志物测试)
- 2021 年 12 月, BioGenex 推出了三种新的一抗免疫组织化学 (IHC) 抗体,包括用于癌症诊断的 CD8A、CD163 和 CD56。
- 2021 年 5 月,GE Healthcare 收购肿瘤生物标志物制造商 Zionexa,以进一步开发用于癌症治疗的分子成像剂。该公司将开发和商业化 Zionexa 生物标记物和正电子发射断层扫描 (PET) 成像剂 Cerianna(氟雌二醇 F-18)。 Cerianna 经美国食品和药物管理局批准用作活检的辅助手段,用于识别雌激素受体 (ER) 阳性病变。它可以帮助为复发性或转移性乳腺癌患者选择最佳疗法。
- 2021 年 4 月,安进推出了 Biomarker Assist,这是一项旨在帮助更多转移性(IV 期)非小细胞肺癌 (NSCLC) 患者的计划)获得生物标志物测试的机会。诊断时的生物标志物测试是让患者接受正确治疗的关键的第一步。通过 Biomarker Assist,符合条件的患者可以节省生物标记物测试费用。
公司简介
- Thermo Fisher Scientific Inc
- F.霍夫曼拉罗氏有限公司
- Illumina 公司
- Bio-Rad Laboratories Inc
- < span style="font-family: verdana、geneva、sans-serif; font-size: 10pt;">QIAGEN
- bioMérieux Inc
- Creative Diagnostics Hologic Inc
- Myriad Genetic Inc
- 探索诊断
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.
Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.
The cancer biomarkers report contains forecast of 2019 to 2027.
The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.
National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.
The List of Companies
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
- Creative Diagnostics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.